| Autor: |
Shoemaker RH; Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick, Maryland 21702-1201, USA. shoemaker@dtpax2.ncifcrf.gov, Scudiero DA, Melillo G, Currens MJ, Monks AP, Rabow AA, Covell DG, Sausville EA |
| Jazyk: |
angličtina |
| Zdroj: |
Current topics in medicinal chemistry [Curr Top Med Chem] 2002 Mar; Vol. 2 (3), pp. 229-46. |
| DOI: |
10.2174/1568026023394317 |
| Abstrakt: |
Increasing insight into the genetics and molecular biology of cancer has resulted in the identification of an increasing number of potential molecular targets for anti-cancer drug discovery and development. These targets can be approached through exploitation of emerging structural biology, "rational" drug design, screening of chemical libraries, or a combination of these methods. In this article we discuss the application of high-throughput screening to anti-cancer drug discovery, with special reference to approaches used at the U.S. National Cancer Institute. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
